Key Takeaways
- Starting menopausal hormone therapy before age 60 or within 10 years of menopause onset generally provides a more favorable balance of benefits versus risks for bothersome hot flashes and night sweats
- Testosterone therapy in women should be guided by a clinical diagnosis of hypoactive sexual desire disorder rather than a low lab value alone
- Genitourinary syndrome of menopause has a range of treatment options, from nonhormonal moisturizers to low-dose vaginal estrogen, vaginal DHEA, and oral ospemifene
- Bone mineral density testing with DXA is recommended starting at age 65, or earlier for postmenopausal women with fracture risk factors
- A November 2026 CME program in Arlington, VA offers in-depth sessions on these exact topics for clinicians treating midlife women
Midlife women bring complicated, overlapping questions to the exam room: Should hormone therapy be considered? Is testosterone worth discussing? What explains the vaginal dryness or bladder changes that won’t resolve? How much does bone health matter right now? Clinicians who stay current on the evidence behind these questions are better positioned to guide patients toward decisions that fit their individual health picture.
Menopause CME Comes to Arlington, VA
A three-day hybrid continuing medical education program, Survival Skills for Women’s Health Fall 2026: Experts Teach Menopause, is scheduled for November 6 through 8, 2026, at The Ritz-Carlton in Pentagon City, Arlington, Virginia. The course is offered both in person and by live stream, and registered attendees receive recorded access afterward, making it workable for busy practices that cannot send everyone to Virginia at once.
The curriculum moves across a wide range of midlife health topics, with sustained attention to menopausal hormone therapy, testosterone, genitourinary syndrome of menopause (GSM), and bone health. World Class CME has organized this program as part of a series that has run for more than 25 years, built around the gap many clinicians describe between residency training and the day-to-day realities of counseling perimenopausal and postmenopausal patients.
The session topics line up closely with questions that come up constantly in gynecology practices: when hormone therapy helps versus when it carries more risk than benefit, how to evaluate testosterone requests without over-relying on lab panels, what distinguishes mild GSM from symptoms needing prescription treatment, and how to build a bone health plan that holds up over years, not just one visit.
Hormone Therapy: Weighing Benefits and Limits
For patients bothered by hot flashes and night sweats, systemic menopausal hormone therapy remains the most effective treatment available, per Mayo Clinic. Whether the benefits outweigh the risks for a given patient depends heavily on two factors: age and how much time has passed since menopause began.
Who Benefits Most, and When
A more favorable risk-benefit balance is generally described for patients who start hormone therapy before age 60 or within 10 years of their final menstrual period. This timing principle shapes much of the modern counseling conversation, since the same therapy that helps one patient manage disruptive symptoms may carry a different risk profile for another who is further out from menopause onset. Hormone therapy can also help prevent bone loss and reduce fracture risk, but it is generally not prescribed solely for that purpose when other suitable treatments exist. A careful patient history, including time since last period, cardiovascular risk factors, and personal preferences, should sit at the center of this decision rather than serve as a single checklist item.
Patients with a uterus who experience postmenopausal bleeding need prompt evaluation to rule out endometrial cancer, and transvaginal ultrasound or endometrial sampling may be used as part of that initial workup, according to the American College of Obstetricians and Gynecologists. Any new bleeding pattern in a patient already on hormone therapy deserves the same level of attention as bleeding in a patient who has never used it.
Protecting the Endometrium with Progestogen
For patients who still have a uterus, systemic estrogen therapy is generally paired with a progestogen. This combination lowers the risk of endometrial hyperplasia and endometrial cancer that can occur when estrogen is used alone in someone with an intact uterus. Patients who have had a hysterectomy are typically offered estrogen alone, since there is no endometrium left to protect.
- Estrogen plus progestogen: appropriate for patients with a uterus, protecting the endometrial lining while still addressing vasomotor symptoms.
- Estrogen alone: appropriate after hysterectomy, when endometrial protection is no longer a consideration.
Getting this pairing right is one of the more consequential prescribing decisions in menopause care, since skipping the progestogen in a patient with a uterus introduces risk that is otherwise avoidable.
Testosterone: Myths vs. Evidence-Based Use
Testosterone therapy for women carries plenty of misconceptions, from assumptions about its effect on energy and mood to expectations about muscle or bone benefits that the current evidence does not support. A global consensus position statement on testosterone therapy for women makes clear that testosterone should not be prescribed on the basis of a low blood testosterone result alone. Blood levels of testosterone in women are difficult to measure reliably and do not correlate well with symptoms, a gap that has pushed lab-driven prescribing out of favor among specialists in this field.
When HSDD Diagnosis Matters More Than Lab Values
The evidence-based indication for systemic testosterone in women is a clinical diagnosis of hypoactive sexual desire disorder, reached after assessing other contributing factors such as relationship issues, medication side effects, mood disorders, and GSM symptoms that may be driving low desire independently. For postmenopausal women with a confirmed HSDD diagnosis, testosterone therapy can improve sexual desire and related outcomes. The same consensus statement draws a firm line on the limits: the evidence does not support using testosterone to improve general wellbeing, cognition, or musculoskeletal health, so prescribing it for those reasons runs ahead of what the data can back up. A thorough history and symptom-focused discussion, rather than a testosterone panel, gives clinicians the more reliable starting point for this conversation.
Recognizing and Treating GSM
Genitourinary syndrome of menopause covers a cluster of symptoms tied to declining estrogen in vaginal and urinary tissues, including dryness, pain with sex, urinary urgency and frequency, and recurrent urinary tract infections. Low-dose vaginal estrogen can treat these symptoms locally, and when GSM is the only indication present, vaginal treatment is generally preferred over systemic hormone therapy, according to a clinical review published in the Journal of the American Medical Association. Recognizing GSM as a distinct, treatable condition rather than an inevitable part of aging is often the first step toward helping a patient who has been quietly living with symptoms for years.
Nonhormonal Moisturizers vs. Prescription Options
For patients with mild symptoms, regular vaginal moisturizers and lubricants used during sexual activity can offer meaningful relief without a prescription. When symptoms are more persistent or bothersome, prescription options come into play after a conversation about preferences and risk tolerance:
- Low-dose vaginal estrogen, available as a cream, tablet or insert, or ring, with symptom improvement usually appearing within a few weeks to months of consistent use, per the Menopause Society.
- Vaginal DHEA, another local hormonal option for GSM symptoms.
- Oral ospemifene, a nonhormonal prescription option taken by mouth rather than applied locally.
Nonhormonal moisturizers are not necessarily replaced once a prescription treatment starts. They can be combined with prescription therapy when symptoms are more severe, giving patients a layered approach rather than an either-or choice.
Matching Therapy to Symptom Severity
Treatment selection works best when it is matched to how much the symptoms are affecting daily life and intimacy, rather than defaulting to the same option for every patient. Mild dryness noticed only occasionally may respond well to a moisturizer used a few times a week. Dryness paired with pain during sex, recurring bladder infections, or urinary urgency that disrupts sleep or daily routines often calls for a prescription option, since those symptoms tend to persist or worsen without targeted treatment. Revisiting the plan at follow-up, rather than assuming the first choice will work indefinitely, keeps care responsive to how a patient is actually doing.
Building a Bone Health Strategy
Bone health often gets less attention in menopause visits than hot flashes or mood changes, yet osteoporosis-related fractures carry serious consequences for independence and quality of life later in life. A practical bone health strategy blends screening, lifestyle habits, and medication when indicated, rather than relying on any single piece.
Screening with DXA and Fracture Risk Tools
Bone mineral density testing is recommended for postmenopausal women age 65 and older, and for younger postmenopausal women who have risk factors for fracture, according to the Bone Health & Osteoporosis Foundation. A DXA scan measures bone mineral density at the hip and spine, with results commonly expressed as a T-score that helps identify osteoporosis and estimate fracture risk. Fracture risk tools can supplement DXA results, particularly for patients whose bone density sits in a borderline range where the scan alone does not clearly point toward or away from treatment.
Alongside screening and medication, everyday habits still matter: weight-bearing and muscle-strengthening exercise, adequate nutrition, fall prevention measures at home, and avoiding smoking are practical, low-cost elements of osteoporosis prevention that apply to nearly every midlife patient regardless of their bone density results.
Choosing Among Antiresorptive and Anabolic Agents
Pharmacologic treatment is recommended for postmenopausal women and men age 50 and older who have had a hip or vertebral fracture, who have a T-score of -2.5 or lower at the femoral neck, total hip, or lumbar spine, or who have low bone mass combined with a sufficiently high fracture risk on a validated tool, per the Bone Health & Osteoporosis Foundation. Bisphosphonates are commonly used as an initial medication for many patients at high fracture risk, though the right choice depends on fracture risk level, contraindications, and patient preference, according to Endocrine Society guidance. Patients taking oral bisphosphonates should take them with plain water on an empty stomach and stay upright for at least 30 minutes, or at least 60 minutes after ibandronate, to reduce esophageal irritation and support absorption.
A fracture occurring during treatment does not automatically mean the medication has failed. Endocrine Society guidance notes that clinicians should reassess adherence, look for secondary causes of bone loss, and reconsider overall fracture risk before switching therapies. Anabolic agents remain an option for patients at very high fracture risk, often considered alongside or after antiresorptive therapy depending on the clinical picture.
Inside the Three-Day Curriculum
The Experts Teach Menopause program is built around a packed schedule that moves from hormone therapy and testosterone on the first day, through bone health, obesity, and cardiovascular disease on the second, and into GSM, migraine, and pelvic floor dysfunction on the third. Sessions include dedicated talks on menopausal hormone therapy, testosterone myths and realities, GSM, bone health pharmacotherapy, nonhormonal treatment of vasomotor symptoms, and sexual wellbeing, reflecting how tightly these topics intersect in real patient visits.
Faculty Behind the Sessions
The program is directed by Steven R. Goldstein, MD, past president of the International Menopause Society and the North American Menopause Society, and James A. Simon, MD, past president of the Menopause Society and the International Society for the Study of Women’s Sexual Health. The broader faculty is multidisciplinary, drawing on expertise in gynecology, primary care, breast health, psychiatry, dermatology, obesity medicine, sexual medicine, neurology, and physical therapy, and includes additional past leadership from the Menopause Society. That range of specialties mirrors the reality that midlife care rarely stays confined to one organ system or one kind of complaint.
Credits, Fees and Who Should Attend
The program awards up to 18 AMA PRA Category 1 Credits and 18 cognate credits. Registration fees are $1,595 for physicians, $1,495 for residents, retirees, military and VA physicians, and $1,295 for advanced practitioners, with separate international rates also listed. The course is designed for physicians, nurse practitioners, physician assistants, and certified nurse midwives committed to midlife women’s health, reflecting the team-based way many practices actually deliver this care.
Individualized Care Remains the Standard
No single protocol covers every midlife patient, which is exactly why hormone therapy decisions, testosterone evaluations, GSM treatment, and bone health planning all hinge on individual history, risk factors, and preferences rather than a one-size-fits-all pathway. Clinicians who keep current on where the evidence has shifted, and where it still draws firm limits, are better equipped to have grounded, specific conversations with patients instead of general reassurances. For a closer, structured look at these topics, consider this menopause-focused CME program for additional clinical detail and practical strategies to bring back into everyday practice.